multiple myeloma, EU and CHMP
News Medical on MSN3d
Interactive atlas unveils immune changes in multiple myelomaMultiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...
The department used its new system for determining whether a condition is service-connected to give affected veterans access ...
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...
Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...
Growing from a small community led initiative to a major fundraiser, the The Walk of Champions began with a modest $12,000 ...
Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback